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INTRODUCTION 
Cystic fibrosis was first described as a disease entity in 1938 
by Dorothy Anderson and was named cystic fibrosis of the pancreas.
1 
It was not until nearly twenty years later that Shwachman and collea-
gues found that over 15 percent of patients diagnosed with cystic 
2 
fibrosis did not have pancreatic involvement. Today, cystic 
fibrosis is recognized as a complex condition involving many 
abnormalities. The classic triad of diagnostic findings includes 
pancreatic insufficiency, obstructive pulmonary disease, and a 
positive sweat chloride test. Other common findings and or conse-
quences of cystic fibrosis are congestive heart failure, sterility or 
3 
decrease fertility, hepatic or biliary cirrhosis, and arthritis. 
Cystic fibrosis is the most common lethal genetic disease of Catica-
3 
sians, occurring in one out of every 2000 births in this population. 
The assumption has been made that this disease is inherited as an 
autosomal recessive trait based on the evidence of population 
4 
genetics data. Recent findings seem to confirm this suspicion by 
location of the common variant of the cystic fibrosis gene on the 
4 
seventh chromosome. Despite advances in both genetic and pharmaco-
logic research as many as one-half of cystic fibrosis patients die by 
20 years of age.^ Also, 90 to 98 percent of mortality in this 
patient population who are one year of age or greater is ascribed to 
3-5 
pulmonary disease. Pulmonary infections requiring hospitalization 
due to decreased pulmonary function remain the leading cause of 
associated morbidity and expense to the patient and their family. 
Pulmonary infection in cystic fibrosis is manifested as a 
chronic obstructive tracheobronchitis, rarely associated with true 
2 
parenchymal involvement. Early changes in pulmonary status appears 
to be related to obstruction rather than infection; however, as the 
disease progresses colonization of the bronchial tree with pathogens 
3*™6 
becomes increasingly common. The primary pathogens of cystic 
fibrosis are Staphylococcus aureas, Pseudomonas aeruginosa, and 
Haemophilus influenzae; however, many other organisms are frequently 
, , 3-6 
detected. At one time it was commonly accepted that Staphylo-
coccus aureas was always the initial colonizing pathogen; however, 
subsequent authors have identified patients with Pseudomonas 
aeruginosa as the first colonizing organism.
6
 As high as 70 percent 
of cystic fibrosis patients in some series have been colonized with 
7 
Pseudomonas aeruginosa. Colonization with Pseudomonas aeruginosa, 
especially the mucoid strains, is associated with a worsening prog-
nosis and a more rapidly progressive disease state. 
Pseudomonas aeruginosa is a Gram-negative, versatile and oppor-
tunistic pathogen. Its mechanisms of virulence include production of 
toxins, hemolysins, adherence factors, and the presence of a poly-
saccharide capsule. The exact contributions of any or all of these 
g 
factors in pulmonary infections has not been clearly delineated , but 
tissue damage secondary to toxin and enzyme production in association 
with immune complex formation has been theorized as a cause. There-
fore, despite the fact that currently available antipseudomonal 
therapy cannot consistently eradicate the causative pathogen from 
sputum or prevent bacterial colonization, it appears that antibiotics 
play a substantial role in reducing morbidity and mortality secondary 





Traditional therapy for pulmonary exacerbations of cystic 
fibrosis has included aggressive chest percussion and postural 
drainage, nutritional support, and antimicrobial therapy. The 
current standard of therapy is usually to administer an aminoglyco-
side plus an extended spectrum penicillin. There are many inherent 
risks with this traditional therapy. The nephrotoxicity of aminogly-
cosides in the adult and pediatric populations is well known, and the 
possible risk of ototoxicity secondary to extended use of aminoglyco-
sides in the cystic fibrosis patient population Is currently under 
investigation. Also, the recurrent development of resistant strains 
of Pseudomonas aeruginosa to presently accepted therapy adds to the 
importance of developing safer and more effective medications for the 
treatment of cystic fibrosis. 
Aztreonam is one of the class of antimicrobials categorized as 
monobactams. Unlike other agents in this group which are isolated 
from bacteria, it is a totally synthetic compound. As with other 
monobactams, aztreonam shows a high degree of resistance to beta-
lactamases. The addition of a carboxylic acid group in the oximino 
moiety and a methyl group at the four position of the bactam nucleus 
precludes any Gram-positive activity but greatly enhances Gram-
negative coverage and stability to beta-lactamases.^ 
Aztreonam binds exclusively to penicillin binding protein three 
(PBP 3). This binding results in the production of long filamentous 
12 13 
cells and ultimately bacterial cell wall lysis. ' This medication 
is active against a narrow spectrum of bacteria consisting of aerobic 
Gram-negative microorganisms. The vast majority of strains of 
Escherichia coli, Serratia spp•, Proteus spp., Klebsiella spp., 
4 
Enterobacter spp., Salmonella spp., Shigella spp., Providencia spp., 
Haemophilus influenzae, and Neisseria gonorrhoeae are susceptible to 
aztreonam.^^ It is also active against the majority of strains of 
Pseudomonas aeruginosa, including most strains that are resistant to 
11 
many other antibiotics. Less than one percent is absorbed orally, 
but after parenteral administration aztreonam penetrates various 
tissues and fluids including bronchial secretions and cerebral spinal 
14.15 
fluid. Glomerular filtration is the primary route of elimina-
tion. Some drug is also eliminated by tubular secretion and two to 
ten percent has been shown to undergo hepatic hydrolysis. The 
half-life of aztreonam from two years of age through adulthood is 
approximately two hours.^ Adverse reactions, as with other beta-
14 15 
lactams, have been minor. * Phlebitis and pain at the injection 
site are rare complications, as are rash and pruritis. Gastrointes-
tinal side effects appear very infrequently. Another concerning side 
effect, asymptomatic increases in liver transaminases appears to be 
transient. The future implications of this will require close obser-
vation. No reports of cross-sensitivity between aztreonam and other 
beta-lactams have been reported. 
Based on the above information and apparent lower evidence of 
nephrotoxicity, aztreonam appears to be a reasonable alternative to 
the traditional therapy utilized for pulmonary exacerbations of 
cystic fibrosis. 
PURPOSE 
The purpose of this study was to evaluate and compare the safety 
and efficacy of aztreonam in pulmonary exacerbations of cystic 
fibrosis associated with Gram-negative pathogens in both pediatric 
5 
and young adult patients to one standard antimicrobial therapy 
consisting of azlocillin and tobramycin. 
MATERIALS AM) METHODS 
This was an open-label, randomized, controlled study evaluating 
the efficacy and safety of aztreonam compared to azlocillin plus 
tobramycin therapy for pulmonary exacerbations of cystic fibrosis due 
to Gram-negative pneumonias. Both the study protocol and informed 
consent form received Institutional Review Board approval prior to 
enrollment of the first patient. Written informed consent (Appendix 
A) was obtained from all patients 18 years of age and older and from 
the parents of younger children. In addition, written assent 
(Appendix B) was obtained from all participants between the ages of 
12 and 18 years. Patient inclusion criteria were: 
1) An informed written consent form must have been signed by 
the patient or legal guardian. 
2) Six years of age or older. 
3) Documented pulmonary exacerbation secondary to a Gram-
negative aerobic organism. 
4) Confirmed bacterial susceptibility of the infecting 
organism to the anti-microbial therapy assigned. 
5) Infection of sufficient severity to justify at least a five 
day hospitalization and treatment with antimicrobial 
agents. 
6) No concurrent administration of antimicrobials having 
aerobic Gram-negative activity. 
7) Non-pregnant or non-lactating females. 
6 
8) No evidence of severe hepatic dysfunction. 
9) No concurrent severe disease that may limit survival time 
during the study period. 
10) No granulocytopenia (ANC < 1000) or evidence of other 
immuno deficiency. 
11) Serum creatinine less than the upper limit of normal for 
age, sex, and weight, or any other evidence of renal 
insufficiency. 
12) No evidence of heart failure. 
13) No history of a type-I allergic reaction to penicillin or 
aminoglycosides. 
Patient Identification and Randomization 
All patients were numbered, in order from one to 22, correspond-
ing to their order of entry into the study. These numbers were used 
to identify the patients throughout the study. Patients were randomly 
assigned to receive aztreonam or azlocillin plus tobramycin based on 
numbers from a random number generator. A total of 22 patients were 
enrolled in the study, with eleven patients in the aztreonam group 
and 11 patients in the control group. Medications for concurrent 
conditions were allowed to be used as necessary during the trial. 
The name of the medication, as well as the dose and route of adminis-
tration, was recorded on the patient's case report form. 
Clinical Evaluation 
Complete history and physical examinations were performed on 
each patient prior to or on the day of enrollment into the study. 
Clinical status evaluations (Appendix C) were performed daily during 
the treatment period and once during the post-treatment period. Each 
7 
patient's maximum daily temperature, blood pressure, heart rate, and 
respiratory rate were obtained prior to enrollment and at least twice 
daily throughout the course of treatment while hospitalized and at 
the post-therapy evaluation. Pulmonary function testing including 
forced vital capacity, forced expiratory volume in one second, 
maximal midexpiratory flow, forced expiratory flow at 75% exhaled 
FVC, and transcutaneous oximetry were performed 48 hours prior to or 
on the day of admission to the study, on the fourth day of treatment 
and once again on the last day of therapy. Pulmonary status 
(Appendix D) was graded with respect to the severity of disease prior 
to, weekly during, and at the follow-up examination using the method 
16 
of Beaudry. Chest x-rays were performed prior to or on the day of 
enrollment, and again on the last day of therapy. Chest x-ray 
results were quantitated by the method of Brasfield et al.^ 
Laboratory Evaluation 
Routine laboratory evaluation was performed 48 hours prior to or 
on the day of admission, every five to seven days during treatment, 
and on the last day of therapy. This battery of laboratory tests 
included hematology evaluation (complete blood count with white blood 
cell differential and platelet count), serum chemistries (electro-
lytes, blood urea nitrogen, creatinine, total protein, albumin, 
glucose, and cholesterol) hepatic profile (liver transaminases, 
alkaline phosphatase, lactic acid dehydrogenase, and total bilirubin), 
and urinalysis (microscopic and macroscopic). Sputum cultures were 
obtained from all patients within 48 hours prior to or on the day of 
enrollment, every fifth day during treatment, and when available, on 
the last day of therapy, as well as at the follow-up visit, seven to 
14 days after therapy. 
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Microbiologic Processing 
All sputum samples collected were processed in the same manner, 
Acceptable samples for analysis were defined as those having fewer 
than ten epithelial cells per low power field and more than 25 white 
blood cells per low power field. Samples were diluted into three 
tubes containing tryptie soy broth to concentrations of 0.01 ml 
sputum per 0.1 ml of tryptie soy broth (1:10) dilution, 0.01 ml of 
sputum per 1 ml of tryptie soy broth (1:100) dilution, and 0.001 ml 
of sputum per 1 ml of tryptie soy broth (1:1000) dilution. Then, 
from the undiluted sputum samples as well as each of the dilutions, 
0.01 ml and 0.001 ml volumes were streaked onto plates containing 
blood, chocolate, and MacConkey agars, representing volumes of 0.01, 
0.001, 0.0001, and 0.00001 ml of undiluted sputum onto each of these 
media. Plates were then incubated for 24 to 48 hours at a tempera-
ture of 35°C. Colonies were then counted after this incubation 
period and were expressed as colony forming units (cfu) per milli-
liter. Individual colonies were then analyzed for pure culture 
identification by placing them in broth and incubating for a total of 
24 hours. At this time the broth was standardized to a 0.5 MacFarland 
g 
standard (representing 5 x 10 cfu per ml for Pseudomonas aeruginosa) 
and smeared on Kirby-Bauer disk diffusion plates. Disks containing 
standard concentrations of selected antimicrobial agents were placed 
on the culture plates. The selected antimicrobial panel included 
aztreonam, azlocillin, tobramycin, gentamicin, cefoperazone, moxa-
laetam, ciproflxoacin, ceftazidime, carbenicillin, piperacillin, and 
amikacin. Serial dilution agar plates were also prepared for 
9 
these same isolates for determination of minimum inhibitory concen-
tration (MIC) of aztreonam. Agar dilution and Kirby-Bauer plates 
were read after another 24 hour incubation period. Aztreonam suscep-
tibility was defined as a disc diffusion zone size equal to or 
greater than 21 mm, and a MIC greater than or equal to 8 mcg/ml. 
Susceptibility was termed intermediate if the zone size was greater 
than or equal to 16 mm but less than 21 mm, and the MIC was equal to 
16 mcg/ml. Resistance to aztreonam was defined as organisms with 
zone sizes less than 16 mm and MIC greater than or equal to 32 
mcg/ml. 
Dosing 
Patients were randomized as described previously and after 
initial assessment and collection of necessary laboratory specimens 
was completed. At this time the subjects received either aztreonam 
(Supplied by E.R. Squibb & Sons, Inc.) or a combination of azlocillin 
plus tobramycin. Aztreonam was given in a dose of 50 mg/kg intra-
venously every six hours, with a total daily dose not to exceed 14 
grams. Tobramycin was given in doses to obtain peak serum concentra-
tions of six to ten mcg/ml and trough concentrations less than two 
mcg/ml. Serum concentrations of tobramycin were adjusted after the 
second or third dose to obtain the above specifications within 48 
hours of starting treatment. Azlocillin was administered in a dose 
of 350 mg/kg per day in four divided doses. Treatment was continued 
for at least five days unless the patient had Gram-negative pathogens 
resistant to the treatment regimen they were receiving, satisfactory 
clinical improvement was not observed in 72 to 96 hours of treatment 
initiation, a serious adverse reaction was noted to the treatment 
10 
medication, or another antibiotic having Gram-negative activity was 
deemed necessary for patients randomized to the aztreonam group. In 
patients with documented or suspected Gram-positive infection, an 
antimicrobial agent with only Gram-positive spectrum was utilized in 
adequate doses. 
Statistical Analysis 
Initial patient demographics of the aztreonam group and the 
control group were evaluated with respect to age, weight, white blood 
cell count, Pseudomonas aeruginosa counts, pulmonary score, clinical 
score, and pulmonary function tests. The two groups were also 
compared for changes from day one to day seven, day one to the last 
day of therapy, and day one to follow-up for the above parameters. 
Brasfield scores were also compared for changes from day one to the 
last day of therapy for both groups. Data comparing day one to last 
day for all above parameters, as well as changes from last day to 
follow-up for Pseudomonas aeruginosa counts were tested for statis-
tical significance utilizing the Mann-Whitney-U test. For all 
statistical tests, the critical level for significance was defined, a 
priori, at 0.05. 
RESULTS 
Patient Demographics and Treatment Course 
Twenty-two patients were initially enrolled in the study. 
Eleven were randomized to the control group (azlocillin plus tobra-
mycin) and eleven to the aztreonam group. Of these initial patients, 
one patient from the control group was not able to complete the study 
secondary to a drug administration error while all patients In the 
11 
aztreonam group completed the study satisfactorily. One patient in 
the control group required that antibiotic administration be discon-
tinued after thirteen days due to rash, fever, and lymphadenopathy 
but was deemed acceptable for evaluation of safety and efficacy 
according to study protocol. Hence, data from twenty-one patients 
were available for analysis. 
The patient population consisted of seven males and four females 
in the azlocillin plus tobramycin group and four males and six 
females in the aztreonam group. Ages ranged from eight to 25 years 
and six to 33 years in the treatment and control groups, respectively 
(means = 14.4, 14.4). Initial white blood cell counts, Pseudomonas 
aeruginosa counts, pulmonary scores, clinical scores, and pulmonary 
function tests were not significantly different between the two 
groups [Mann-Whitney-U, p > 0.05 (Table 1)]. 
All patients received vitamin supplements and pancreatic enzymes. 
Other medications received by some patients included theophylline, 
ranitidine, cimetidine, phenytoin, vitamin K, diflunisal, oxandrolone, 
and systemic and inhaled bronchodialators (terbutaline and metapro-
terenol). In addition, six patients in the aztreonam group required 
antistaphylococcal coverage, two with oral dicloxacillin and four 
with intravenous nafcillin. Pulmonary toilet was performed four to 
five times daily. At follow-up, eighteen patients were available; 
eight from the aztreonam group and ten from the control group. The 
duration of therapy for the two groups ranged from 11 to 22 days 
(mean 15.7) and 10 to 28 days (mean 16.3) from control and treatment 
patients respectively. Of these, the control group had an average of 
5.4 days of outpatient treatment compared to 5.6 days in the 
aztreonam group. 
12 
Clinical and Laboratory Results 
Patients in both groups showed varying degrees of response to 
their regimens during the course of the study. Differences in 
clinical scores between day one and the last day of therapy, were not 
statistically significant between the two groups (Table 2). Also, 
the change in clinical scores from day one to day seven in the 
aztreonam group and the azlocillin plus tobramycin group were similar 
with a mean t standard deviation of -2.6 ± 1.4 and -2.5 ± 1.8 
respectively. Likewise, differences in pulmonary scores from day one 
and the last day of therapy also did not reach statistical signifi-
cance (Table 3), with changes from day one to day seven again showing 
similarity. Brasfield chest x-ray scores for the two groups compar-
ing day one and last day again revealed no statistically significant 
difference (Table 4). A comparison of pulmonary function testing 
between the two groups evaluating forced vital capacity (FVC), forced 
expiratory volume in one second (FEV), maximal midexpiratory flow 
(FEF^^,.), and forced expiratory flow at 75% exhaled FVC (FEF^„) 
again failed to show a statistically significant difference when 
comparing values for day one and the last day of therapy (Tables 5 
and 6). Mean change from day one to day four in FVC and FEV^ for the 
aztreonam group and the azlocillin plus tobramycin groups were 
10.9,11.5 and 8.3,8.4 respectively. Oximetry studies comparing day 
one and day four revealed no statistical difference between the two 
groups. Unfortunately, only nine of twenty-one patients had oximetry 
performed on the last day of the study, and hence these data were not 
conclusive (Table 7). Analysis of white blood cell counts from day 
13 
one to day last and from day one to follow-up again revealed no 
statistical difference between the two groups (Table 8). 
Microbiological Evaluation 
All patients had at least one strain of Pseudomonas aeruginosa 
isolated from their sputum on the first day of the study. Patients 
in the control group had a total of seventeen strains of Pseudomonas 
aeruginosa, eight of which were of the mucoid variety, while the 
aztreonam patients had twenty-two strains, 10 of which were of the 
mucoid variety. The geometric mean minimum Inhibitory concentration 
(MIC) of all Isolates of Pseudomonas aeruginosa in both treatment 
groups to aztreonam was 1.59 mcg/ml, while the geometric mean of 
patients in the aztreonam group only, was 1.05 mcg/ml on the day of 
entry into the study. Of the eleven patients in the aztreonam group 
all eleven were able to produce sputum samples on day seven of 
therapy, ten patients produced sputum on the last day, and one on 
follow-up evaluation. Of the ten patients receiving azlocillin plus 
tobramycin, all ten produced sputum on day seven of therapy, eight on 
the last day, and eight on follow-up examination, Six patients in 
the aztreonam group accounted for all eight strains of Pseudomonas 
aeruginosa isolated from this group on the last day of therapy. Of 
these, six strains were resistant to aztreonam with a geometric mean 
MIC of 20.7 mcg/ml. Five patients in the control group accounted for 
all ten strains of Pseudomonas aeruginosa isolated from this group. 
Of these, eight strains were found to be resistant to azlocillin and 
four were resistant to tobramycin. The geometric mean MIC of 
isolates in this group to aztreonam as 12.5 mcg/ml. On follow-up 
evaluation seven patients in the treatment group produced ten 
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Isolates of Pseudomonas aeruginosa. All strains were sensitive to 
aztreonam, with a geometric mean MIC of 1.19 mcg/ml. Seven Pseudo-
monas aeruginosa isolates were found in the control group. Four of 
these were found to be resistant to azolocillin and three to tobra-
mycin. 
Percent change in Pseudomonas aeruginosa counts (log^ cfu/ml) 
from day one to day seven, day one to last day, and day one to 
follow-up are listed in Table 9. These data revealed no statistical-
ly significant difference between day one and the last day of therapy 
when evaluating both groups. Also no difference was seen when 
comparing value changes from the last day of therapy to follow-up 
evaluation (p > 0.05). Intra-group differences for both groups did 
reveal a statistically significant drop in Pseudomonas aeruginosa 
counts comparing day one to day seven, but this difference was not 
present in either group at follow-up examination. 
Pseudomonas cepacia was isolated from three patients in the 
control group and from one in the aztreonam group on day one of 
therapy. Two patients in the aztreonam group had new isolates of 
Pseudomonas cepacia documented on day seven. Two patients in the 
control group and one in the study group had Pseudomonas cepacia 
isolated from day one through follow-up evaluation. One strain of 
Pseudomonas cepacia was found to be susceptible to aztreonam while 
all others were resistant. The geometric mean MIC of all isolates of 
Pseumonas cepacia on the first day of the study to aztreonam was 12.6 
mcg/ml. This increased to 26.4 mcg/ml by the last day of the study. 
The number of isolates of Pseudomonas aeruginosa per patient, 
the number of mucoid strains per patients, and the number of 
15 
Pseudomonas cepacia strains per patient in each group were not 
statistically different (p > 0.05). Five patients were not evaluable 
at follow-up, three in the aztreonam group and two in the azlocillin 
plus tobramycin group. The reason for patients not being available 
for follow-up were either that the patient was not able to produce 
sputum as documented earlier in this section or that they did not 
return for follow-up. 
Safety 
One patient in the azolocillin plus tobramycin group required 
that therapy be discontinued after eleven days due to rash, lymph-
adenopathy and fever. No increase in eosinophils or shortness of 
breath was noted at that time. Alkaline phosphatase values were 
elevated at the day of entry into the study and remained so for the 
duration in all but two patients in the aztreonam group and one 
patient in the azlocillin plus tobramycin group. Four patients in 
the control group (40%) demonstrated abnormal liver transaminase 
values compared to eight (72%) in the aztreonam group. However, only 
two patients in the control group actually had increases above the 
normal range, while all eight patients in the aztreonam group had 
increases above the normal range. Liver transaminases in these 
patients increased by two to four times normal by day seven to 
fourteen of the study. All values for both groups returned to 
baseline by the time of follow-up examination. No other adverse 
effects or laboratory changes reflecting side effects were noted. 
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DISCUSSION 
Traditionally, acute pulmonary exacerbations of cystic fibrosis 
due to bacterial pneumonias are treated with intensive pulmonary 
toilet and antibiotics. Evidence that antibacterial treatment plays 
a significant role in improving both quality and length of life is 
still debated. However, antimicrobial therapy does appear warranted, 
despite the relative infrequency with which total eradication of 
microorganisms is a c h i e v e d . ^ ' I n light of previous data indicat-
ing that aztreonam may be an effective agent in acute pulmonary 
1 Q ?n 
exacerbations, this study set out to evaluate this in a con-
trolled comparison trial against an accepted traditional therapy, 
azlocillin plus tobramycin. Historically, studies have used subjec-
tive criteria to evaluate clinical response to antibiotic therapy,"* 
as this study has done. In addition, this study also used quantita-
tive, objective evaluation to assess the status of the patients' 
Infection (e.g. white blood cell count, microorganism densities and 
minimum inhibitory concentration data). With this type of evaluation 
method, accurate and reliable results should be produced by reducing 
the influence of investigator bias and by providing evaluation of 
known objective parameters that are most closely reflective of the 
changes expected with antimicrobial treatment. 
Admitting characteristics of each group revealed no statistical-
ly significant differences with respect to age, weight, clinical 
score, pulmonary score, Pseudomonas aeruginosa count, or white blood 
cell count. Hence, the two groups were indeed comparable at the 
outset of the study and therefore the azlocillin plus tobramycin 
group served as a valid control for this study. Clinical scores and 
17 
pulmonary scores revealed no significant difference statistically in 
response to either therapy when comparing day seven and the last day 
of therapy against baseline values. In reviewing intra-group data, 
improvement was demonstrated from baseline for both groups at all 
study intervals. These data suggest that aztreonam is as effective 
as conventional therapy when evaluating subjective patient parameters. 
Pulmonary function testing showed no statistically significant 
difference between the two groups at any of the evaluation intervals. 
Interestingly neither group showed any evidence of improvement of any 
of the pulmonary function testing parameters. This data is incon-
21 22 
sistent with other investigators, ' who found that pulmonary 
function tests improve with hospitalization and the use of antibiotic 
treatment. This discrepancy may be a reflection of the small number 
of patients studied. Another possible factor influencing the test 
results is that the younger patients in this study often do not 
perform these tests reliably. However, this is not supported by the 
fact that even the most sensitive and patient technique independent 
measures of small airway function (FEF^ ^ and FEF^^) did not 
demonstrate any improvement. Therefore, pulmonary function tests In 
this study did not appear to correlate well with other measures of 
clinical change in patient status. Oximetry studies did not provide 
any useful insight into the influence of therapy on oxygenation 
because of the great number of missing values (Table 7). 
Statistical significance was not reached when comparing 
Brasfleld chest x-ray scores. Both groups did demonstrate intra-
group improvement from baseline to the last day of the study, which 
is consistent with improved lung function, decreased mucus plugging 
18 
and improved air exchange despite the lack of evidence of improvement 
on pulmonary function testing. 
No difference was found when comparing changes in white blood 
cell counts between the two groups at any evaluation point in the 
study. Intra-group improvement did reach statistical significance at 
day seven and at the last day of therapy for both groups. Reduction 
in peripheral leukocytosis seems to be consistent with a clinical 
response to therapy even though systemic manifestations of infection, 
such as fever and peripheral leukocytosis are present in only one-
third of cystic fibrosis patients with acute pulmonary exacerba— 
5 22 23 
tions. Two studies ' found a high degree of correlation between 
resolving peripheral leukocytosis and clinical improvement. Our data 
did reflect clinical improvement based on reduction in peripheral 
leukocytosis for both groups. 
Percent reduction in Pseudomonas aeruginosa colony counts did 
not show any statistically significant change between the two groups 
when comparing entry data to that on day seven, the last day of 
therapy and on follow-up. Intra-group decreases in colony counts did 
reach statistical significance for both groups when comparing day 
seven and last day values with entry data. However, neither group 
was able to demonstrate significant decreases at follow-up. These 
data imply that despite the ability to decrease the density of 
Pseudomonas aeruginosa during therapy, neither regimen was able to 
prevent further regrowth of the microorganism after cessation of 
therapy. This finding is explained by the fact that only a few 
patients in either group showed a complete eradication of organism by 
the last day of therapy. We also found, as have other investigators, 
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that improvement in clinical scores were not always associated with 
22 23 
microbiological response to therapy. * These findings suggest 
that factors other than antibiotics, such as pulmonary toilet, 
hydration, and nutritional support play an important role in the 
treatment of exacerbations in cystic fibrosis. Also, perhaps a 
decrease in the number of colonies of Pseudomonas aeruginosa may 
produce a subsequent decrease in the amount of virulence factors 
released e.g. exotoxins, hemolysins, and elastases which have been 
shown to produce localized tissue destruction and decrease in lung 
g 
function over time. Alginate production has also been associated 
g 
with Pseudomonas aeruginosa infections in cystic fibrosis. Alginate 
accounts for the mucoid appearance of some strains. This has been 
shown to influence the susceptibility of the microorganism to phago-
cytosis or antibody mediated response. Hence, mucoid strains are 
g 
traditionally associated with a worsening prognosis. Colonization 
with mucoid strains in our patient population was very close to the 
g 
average of 80 percent. However the presence of mucoid strains was 
not associated with a worse short term medical outcome in either 
group. Still another contributing factor may be that the organisms 
cultured during therapy or at follow-up may be strains that are less 
virulent. 
The geometric mean MIC of Pseudomonas aeruginosa in both groups 
remained fairly constant at day one and at follow-up, however, at day 
seven the geometric mean MIC increased to 12.7 mcg/ml and 20.7 mcg/ml 
in the control and treatment groups, respectively. Because both 
groups of patients showed relative increases in the MIC and the fact 
that aztreonam is not known to induce beta-lactamase production, at 
20 
least by a plasmid mediated mechanism, the most likely cause of this 
result is selection of resistant organisms via one of the other known 
mechanisms of beta-lactam resistance. Chromosomal production of 
beta-lactamase or altered permeability of the drug into the cells are 
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possibilities. Full evaluation of the effects of antimicrobial 
therapy on the selection of resistant organisms requires further 
investigation. All strains of Pseudomonas cepacia proved to be 
resistant with a geometric mean MIC that consistently increased with 
24 25 
continued treatment which is consistent with other reports. ' 
Despite this, the presence of Pseudomonas cepacia did not appear to 
be associated with worse therapeutic outcome in either group. Many 
cystic fibrosis centers are reporting increased colonization rates, 
but the consequence of colonization with Pseudomonas cepacia remains 
controversial.^ 
No evidence of nephrotoxicity was observed in the azlocillin 
plus tobramycin group as evidenced by increase in serum creatitlne or 
changes in urinalysis. One patient in this group did develop a rash 
with lymphadenopathy and fever on day eleven of therapy which could 
have been due to a delayed hypersensitivity reaction to either the 
tobramycin or azlocillin. 
Transient elevation in liver transaminases were most significant 
in the aztreonam group. Eight out of eleven patients in this group 
had demonstrable increases on day seven of therapy compared to only 
two In the azlocillin plus tobramycin group. All transaminases 
returned to baseline by follow-up evaluation. The percentage of 
patients with increases in liver transaminase values due to aztreonam 
11 25 
is significantly higher than that reported in other studies. ' 
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None of the patients in this study demonstrated any clinically 
evident compromise in hepatic function. Why liver transaminases rise 
in this setting, and the significance of this change if any, remains 
to be elucidated. Future studies with large population samples may 
yield this information. 
Finally, type II error needs to be considered in this study. 
The small sample size in this investigation increases the possibility 
of concluding that a difference does not exist when in fact there is 
a real difference. This can be exemplified by the fact that in order 
to detect a difference of ten percent in the reduction of Pseudomonas 
aeruginosa counts, the number of patients in each group would need to 
be ninety-five. This assumes type II error was set at beta = 0.2. 
Similar numbers are obtained when evaluating the other parameters in 
this study. Hence caution should be used in extrapolating this data 
to other patient populations until more data are available. 
CONCLUSION 
In this patient population we found aztreonam to be as effective 
in the treatment of pulmonary exacerbations In cystic fibrosis as 
traditional therapy by all measured parameters. Resistance was no 
more likely to this single agent than to conventional therapy which 
suggests that aztreonam may be an effective single drug therapy of 
pulmonary infections with Pseudomonas aeruginosa. Neither regimen 
was able to eradicate microorganisms from sputum for a sustained 
length of time. Hence, complete eradication of microorganisms from 
the sputum and bronchopulmonary tree of patients with cystic fibrosis 
still remains a rarely achieveable goal. The issue of whether 
22 
aztreonam offers longer hospital free or antibiotic free periods is 
not answered by these data. Also, further research is needed to 
examine whether treatment with aztreonam or other antibiotics selects 
out resistant strains of Pseudomonas aeruginosa. Aztreonam does 
offer the benefit of a reported lesser incidence of nephrotoxicity 
than conventional therapy. The clinical significance of the 
transient rise in liver transaminases will require large populations 
use to delineate. This is the most worrisome of the reported side 
effects of aztreonam and will require close observation. 
TABLES 
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TABLE 1. Patient Demographics 
Aztreonam Patients 
Age Weight Clinical Pulmonary Colony Count White Blood Cell 
(yrs) (Kg) Score Score (loglO cfu/ml) Count (xlOOO) 
DS 15 53.3 12 4 11 12.0 
cs 18 34.5 15 8 6 13.9 
JC 12 40 10 3 5 5.8 
RM 16 42.8 13 5 23 9.5 
LM 15 42 14 8 15 9.3 
TK 12 43.8 10 5 10 13.0 
CC 6 15 13 8 15 15.3 
JB 10 21 10 7 7 13.4 
KS 11 25 9 6 14 19.7 
BB 10 43.9 9 3 16 10.3 
EA 33 65.1 11 8 17 8.8 
Mean 14.4 38.7 11.5 5.9 12,5 11.7 
± SD 7.0 14.3 2.1 2.0 5.5 3.9 
Control patients 
KS 19 53 13 15 11 12.0 
MS 8 22 11 4 9 5.8 
LG 21 47 13 9 8 18.1 
BF 14 48.5 14 10 18 10.6 
SK 11 21 12 8 22 14.0 
RS 16 52 12 7 5 7.0 
TB 14 35 7 3 8 7,1 
SB 9 32 11 6 14 13.4 
NM 25 51 12 9 14 13.3 
JR 9 26 9 3 17 8.8 
Mean 14.4 37.6 11.2 7.7 13.5 10.6 
± SD 5.4 12.9 2.1 3.7 5.8 3.8 
Mann-Whitney-U, p > 0.05 
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TABLE 2. Clinical Scores 
Aztreonam Patients 







DS 12 7 7 -5 -5 
CS 15 14 10 -1 -5 
JC 10 7 8 -3 -2 
RM 13 10 8 -3 -5 
LM 14 10 7 -4 -7 
TK 10 8 8 -2 -2 
CC 13 10 8 -3 -5 
JN 10 8 7 -2 -3 
KS 9 9 8 0 -1 
BB 9 6 - -3 -
EA 11 8 8 -3 -3 
Mean 11.5 8.8 7.2 -2.6 
* 
-3.6 
± SD 2.3 2.8 1 .3 1.4 2.8 
Control Patients 
KS 14 9 11 -5 -3 
MS 11 7 6 -4 -5 
LG 13 11 8 -2 -5 
BF 14 10 9 -4 -5 
SK 12 10 10 -2 -2 
RS 12 11 9 -1 -3 
TB 7 7 6 0 -1 
SB 11 9 9 -2 -2 
NM 12 8 _ -4 -
JR 9 - - - -
* 
Mean 11.5 9.1 8.5 -2.5 -3.0 
± SD 2.1 1.6 1.1 1.8 1.8 
a 
Indicates means compared for statistical significance, Mann-Whitney-U. 
Result: p > 0.05 
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TABLE 3. Pulmonary Scores 
Aztreonam Patients 
Change Day One Change Day One Change Day 
to Day Seven to Day Last to Follow-
DS -2 -2 -2 
cs 0 -1 -5 
JC -1 -I _ 
RM +2 -2 -3 
LM -3 -5 -5 
TK -3 -3 -
cc -1 -4 -5 
JN -1 -4 -4 
KS -1 -4 -3 
BB -1 -2 -2 
EA -3 -6 -6 
* 
-3.89 Mean -1.27 -3 .09 
± SD 1.5 1.4 1.5 
Control Patients 
KS -5 -2 -1 
MS -2 -2 0 
LG -2 -5 -3 
BF -4 -8 -2 
SK -4 -6 -
RS 0 -1 -2 
TB 0 0 -2 
SB 0 -4 -3 
NM -3 _ -4 
JR -1 -1 + 1 
Mean -2 .54 
* 
-3.22 -1.77 
± SD 2.3 2.7 1.6 
£ 
Indicates means compared for statistical significance, Ma-Whitney-U 
Result: p > 0.05 
TABLE 4 . Brasfleld Chest X-Ray Scores 
Aztreonam Patients Control Patients 
Day One Day Last Day One Day Last 
DS 19 20 KS — ^  
cs 12 13 MS 19 20 
JC 20 19 LG 14 17 
RM 22 22 BF 19 21 
LM 19 20 SK 15 19 
TK 18 20 RS 16 18 
cc 10 16 TB 22 — 
JN 11 17 SB 22 24 
KS 16 16 NM 13 13 
BB 22 22 JR 19 20 
EA 17 20 
Mean 16.9 18.6 17.7 19.0 
± SD 4.2 2.8 3.3 3.2 
Mann-Whitney-U, p > 0.05 
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TABLE 5. Forced Vital Capacity and Forced Expiratory Volume 
in One Second (Percent Predicted) 
Aztreonam Patients 
Change in Change in Change in Change in 
FVC Day One FVC Day One FEV1 Day One FEV1 Day One 
to Day Four to Day Last to Day Pour to Day Last 
DS 6 3 15 11 
CS 17 8 11 8 
JC -23 -36 6 -5 
RM -4 - 4 3 -4 
LM -10 1 -9 -2 
TK 6 7 13 9 
CC -13 13 2 14 
JN — 11 — 21 
KS — - 3 — 0 
BB — 6 — 3 







KS 0 -2 3 3 
MS 10 1 5 1 
LG 7 5 6 12 
BF 13 14 13 15 
SK 11 18 15 22 
RS 2 10 -1 10 
TB 6 3 10 9 
SB 11 20 3 14 
NM 2 11 - 1 4 






Indicates means compared for statistical significance, Mann-Whitney-U, 
Results: p > 0.05 for both FVC and FEV1 
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TABLE 6. FEF 25% - 75% and FEF 75% (Percent Predicted) 
Aztreonam Patients 
Change in FEF 25%-75% Change in 
Day One to Day Last Day one to 
DS 32 24 
CS - 1 1 
JC 1 - 9 
RM - 4 4 
LM - 7 - 5 
TK -12 23 
CC 11 14 
JN 54 39 
KS 4 4 
BB 1 8 





KS - 1 0 
MS 15 14 
LG 10 8 
BF 21 18 
SK 15 7 
RS 6 5 
TB 27 25 
SB -13 -28 
NM 4 3 





Indicates means e d for statistical significance, Mann-Whitney-U 
Results: p > 0.05 
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TABLE 8. White Blood Cell Counts (X 1000) 
Aztreonam Patients 
Day One Day Last Day Follow-Up 
Change Day 
One to Day 
Last 
Change Daj 
One to Da] 
Follow-Up 
DS 8.7 12 .2 5.0 - 3.1 - 3.7 
c s 13.9 8.1 12.5 - 5.8 - 1.4 
JC 5.8 4.5 not done - 1.3 not done 
RM 9.5 7.6 9.7 - 1.9 0.2 
LM 9.3 8.1 7.8 - 1.2 - 1.5 
TK 13.0 8.5 not done - 2.5 not done 
CC 15.3 8.3 12.0 - 7.0 - 3 . 3 
J N 13.4 6.1 10. 1 - 7.3 - 3.3 
KS 19.7 7.4 14.1 - 12.3 - 5.6 
BB 10.3 6.8 8.2 * 3*5 - 2.1 
EA 8.8 6.2 7.9 - 2.4 - 0.9 
Mean 10.9 7.6 9.7 
* 
- 4.5 - 2,4 
± SD 3 . 4 1.7 
Control Patients 
KS 12.0 12.2 not done 0.2 not done 
MS 5.8 3.9 5.7 - 1.9 - 0.1 
LG 18.1 11.5 18.6 - 6.6 0.5 
BF 10.6 6.6 6.8 - 4.0 - 3.8 
SK 14.0 9.0 not done - 5.0 not done 
RS 7.0 4.4 4.9 - 2.6 - 2.1 
TB 7.1 6.7 4.4 - 0.4 - 2.7 
SB 7.7 6.5 7.2 - 1.2 - 0.5 
MM 13.3 13.9 14.0 0.6 0.7 
JR 7.8 6.2 9.7 - 1.6 1.9 




± SD 2.3 1.9 
Indicates means e d for statistical significance, Mann-Whitney-U, 
Results: p > 0.05 
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TABLE 9. Percent Reduction in Pseudomonas Aerug >inosa Counts 
(log ^  cfu/ml) 
Aztreonam Patients 
Day One to Day One to Day One to 
Day Seven Day Last Follow-Up 
DS -22 77 0 
CS 66 100 — 
JC 100 100 — 
RM 70 100 39 
LM — 4 0 * 
TK 40 NS NS 
CC 20 - 6 13 
JN 71 14 - 28 
KS 85 57 100 
BB 75 87 87 
EA 70 88 16 
54.7 
** 
Mean 73.7 40.7 




















































No sputum production 
* 
Indicates means compared for statistical significance, Mann-




INFORMED CONSENT FORM 
Aztreonam vs Tobramycin Plus Azlocillin in Cystic Fibrosis 
Date 
PURPOSE OF STUDY: 
The purpose of the research study in which you are being invited to 
participate is to compare the effectiveness and safety of aztreonam, 
a new antibiotic, to the usual antibiotics used to treat lung 
infections associated with cystic fibrosis, namely tobramycin and 
azlocillin. Effectiveness and safety of the two antibiotic regimens 
will be evaluated based on both clinical and laboratory tests. 
DESCRIPTION OF PROCEDURES: 
One-half of the 30 patients enrolled in this study will receive 
aztreonam and the remainder will receive tobramycin and azlocillin. 
Treatment will be assigned on a random basis and thus neither you nor 
the investigators will have any control over which drug(s) you are 
treated with. 
Should you decide to participate in this study, you will receive one 
of the two antibiotic regimens for the usual course of therapy 
(generally 10 to 14 days). All of the drugs are given intravenously. 
We will ensure that the bacteria growing in your sputum are sensitive 
to the antibiotics with which you are being treated. If they are 
not, you will be taken off the study and more appropriate drugs will 
be prescribed. You do not have to remain in the hospital for your 
entire course of therapy. You will be asked to return to the cystic 
fibrosis clinic a week or two after the completion of your antibiotic 
therapy for a follow-up exam. 
On the day of starting therapy, you will receive a physical examina-
tion and your medical history will be recorded. Your clinical 
progress will be assessed daily while you are in the hospital. 
Additionally, blood, urine and pulmonary function tests will be 
performed on the first day of treatment and then periodically during 
treatment. More specifically, blood (about one and one-half tea-
spoonfuls) and urine tests will be performed every 5 to 7 days during 
and at the end of therapy. 
Pulmonary function tests (non-invasive tests of lung function) and 
ear oximetry (a non-invasive method to test the amount of oxygen in 
your blood) will be done at the beginning, on day 4 and at the end of 
therapy. Chest x-rays will be done on the first and last days of 
therapy. 
Pregnant or nursing mothers should not participate in this study. If 
you are unsure whether you are pregnant, we will test you. Non-
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pregnant females of child-bearing age who are using a reliable form 
of contraception are eligible to take part in this study. 
Neither you nor your medical insurance company will be charged for 
the tests done solely for the purposes of this study. Additionally, 
aztreonam is being supplied at no charge. As you are being asked to 
return to the hospital for a follow-up visit, we will pay you $50 to 
make up for your inconvenience, travel expenses, and lost work time 
if you complete this last phase of the study. 
RISKS AND BENEFITS; 
The potential benefits of participating in this study include a more 
detailed and thorough evaluation of your disease and course of 
therapy and possible treatment with a new antibiotic that appears to 
be safer and at least as effective as conventional therapy (for 
example, tobramycin and ticarcillin). Risks of participating are 
limited to the potential side effects of aztreonam which include 
rash, itching, upset stomach, diarrhea, pain at injection site (in 
the vein in which the drug is administered) and transient elevation 
of some liver enzymes. Liver enzymes are substances produced in the 
liver and reflect its metabolic activity. Elevations in these 
enzymes secondary to antibiotic therapy are common, have no specific 
significance and revert to normal once the antibiotic is withdrawn. 
ALTERNATIVE CARE: 
If you do not wish to participate in this study, you will receive 
normal care and treatment for your current infection, including the 
use of marketed antibiotics. Failure to participate will not result 
in any prejudice to your current or future medical care. 
CONFIDENTIALITY: 
All information gathered in this study will be held in strict 
confidence. While such information will be used for medical and 
scientific purposes including publication, your identity will not be 
revealed. 
Additionally, this information will be available for inspection by 
the sponsor (E.R. Squibb & Sons, Inc.) and the Food and Drug 
Administration. 
FURTHER INFORMATION: 
Should you have other questions during or after this study you may 
contact Dr. John Bosso (581-7545 or 942-4525; a 24 hour number) or 
Dr. Phil Black (581-2810). If problems arise that you do not wish to 
discuss with one of the investigators, you may contact the 
University's Institutional Review Board at 581-3655, 
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LIABILITY; 
In the event you sustain physical injury resulting from the research 
project in which you are participating, the University of Utah will 
provide you, without charge, emergency and temporary medical treat-
ment not otherwise covered by insurance. Furthermore, if your 
injuries are caused by negligent acts of omission of the University 
employees acting in the course and scope of their employment, the 
University may be liable, subject to limitations prescribed by law, 
for additional medical costs and other damages you sustain. If you 
believe that you have suffered a physical injury as a result of 
participating in this research program, please contact the Office of 
Research Administration at 581-6903. 
VOLUNTARY PARTICIPATION: 
Your participation in this study is totally voluntary and your are 
free to withdraw at any time without prejudice to further medical 
care. 
CONSENT TO PARTICIPATE: 
In signing below, you agree to participate as a research subject in 
this study and acknowledge the fact that you have has a fair 
opportunity to ask questions about the above mentioned procedures. 
You will be given a copy of this form. 
Patient name: Signature: 





Aztreonam vs Tobramycin Plus Azlocillin in Cystic Fibrosis 
Date 
You are being asked to participate in a research study. Whether you 
participate is up to you; you are under no pressure of obligation to 
do so. 
We are evaluating a new antibiotic for cystic fibrosis called aztreo-
nam by comparing it to the usual antibiotics used for this disease, 
namely tobramycin and azlocillin. Therefore, if you are in the study 
you will receive either aztreonam or tobramycin and azlocillin. 
Should you agree to participate, in addition to receiving antibiotics, 
we will collect a small amount of blood, urine and sputum every 5 to 
7 days during and at the end of treatment. The blood is obtained 
with a needle which is inserted into a blood vessel in your arm which 
may cause a small amount of pain or a bruise. The results of these 
tests allow us to see how well you are responding to the antibiotics. 
Also, we will test the function of your lungs (with pulmonary func-
tion tests) and the amount of oxygen in your blood (no blood is 
necessary for this test) on the first, fourth and last of treatment. 
These tests cause no pain or discomfort. 
If you do not chose to participate in this study, you will have your 
normal hospitalization and treatment with antibiotics. Many of the 
tests mentioned above will be done but not on a regular schedule. 
There are no additional risks (over what you have with your normal 
hospitalization and treatment) with this study. The experimental 
drug appears to have less frequent and less serious side effects than 
normal antibiotic therapy (for example; tobramycin and ticarcillin). 
The advantages to being in the study are that we follow your progress 
very closely and that aztreonam is safer and possibly more effective 
than the usual antibiotics. 
It is important for you to remember that it is totally up to you 
whether or not you volunteer for this study and that you can drop out 
at any time you want to. Your parents are also being asked for their 
permission for you to participate. 
In signing this form you are acknowledging that we have explained 
what this study involves, what procedures will take place and what 
risks and benefits of participating are and that you voluntarily 
agree to participate. You are also acknowledging that we have 
answered your questions about the study. 
Patient Name Signature 
APPENDIX C 
Pulmonary Status Scoring Form 
KEY TO INTENSITY OF SIGNS/SYMPTOMS 
1 m  Norm«irAbl*ni 3 m  MoO«f«M Ch*ngM/CI*(rly Pllhoio()cil 
2 » V*ry Mild Clwngai/StlgM 4 - Savara Cfcmgai/MlgWr Pimologlcal 
COUOH • • • • 
RAIES/HHONCHI • • • 
CUIUS • • • 
consolidation; 
PLEURAL 
EFFUSION • • • 
DSCREASIB 
PULMONARY 
FUNCTION • • • • 
SYMPTOMS 
BELATED TO 
BRONCHITIS • • • • 
Othar (apaclfy) • • • • 
Ollwr OpKllY) • • • 
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APPENDIX D 
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